A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C
M Rumi, E Del Ninno, M L Parravicini, R Romeo, R Soffredini, M F Donato, J Wilber, A Russo, M Colombo – 1 December 1996 – To compare the long‐term effectiveness and tolerability of lymphoblastoid interferon (IFN‐αN1) and recombinant interferon alfa 2a (IFN‐α2a) in patients with chronic hepatitis caused by hepatitis C virus (HCV), 234 consecutive patients with HCV‐related chronic hepatitis were randomized prospectively to receive titrated doses (starting dose = 6 million units [MU]) of IFN‐α2a (n = 118) or IFN‐αN1 (n = 116) for 12 months.